Pharming (PHAR) Cost of Revenue (2020 - 2026)
Pharming (PHAR) posted Cost of Revenue of $6.6 million for Q1 2026, down 100.0% on a QoQ basis from $21100.0 billion in Q4 2025, and up 79826885.46% year-over-year from N/an in Q1 2025.
Pharming (PHAR) Cost of Revenue (2020 - 2026) Analysis & Trends
Pharming's Cost of Revenue history runs 7 years deep, the most recent figure standing at $6.6 million for Q1 2026.
- Quarterly Cost of Revenue rose 79826885.46% year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28200.0 billion (up 21.55% YoY) and the FY2025 annual result came in at $45.5 million, up 28.53% from the prior year.
- Cost of Revenue was $6.6 million for Q1 2026 at Pharming, down from $21100.0 billion in the prior quarter.
- Across five years, Cost of Revenue topped out at $23200.0 billion in Q4 2024 and bottomed at $6.8 in Q3 2024.
- A 5-year average of $3358.8 billion and a median of $16.4 million in 2024 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2024 — Cost of Revenue slumped 100.0% — and 2025, when it surged 104411764705782.36%.
- Pharming's Cost of Revenue stood at $17.6 million in 2022, then jumped by 43.25% to $25.2 million in 2023, then jumped by 92019573.17% to $23200.0 billion in 2024, then retreated by 9.05% to $21100.0 billion in 2025, then plunged by 100.0% to $6.6 million in 2026.
- Business Quant data shows PHAR's Cost of Revenue at $6.6 million in Q1 2026, $21100.0 billion in Q4 2025, and $7100.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 121.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Pharming | 8.69 Bn | 8.64 Bn | 65.80 Mn | 6.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.64 Mn |
| Mar 31, 2026 | 6.64 Mn |
| Dec 31, 2025 | 21,100.00 Bn |
| Dec 31, 2025 | 21,100.00 Bn |
| Sep 30, 2025 | 7,100.00 Bn |
| Sep 30, 2025 | 7,100.00 Bn |
| Jun 30, 2025 | 17.30 Mn |
| Jun 30, 2025 | 17.30 Mn |
| Mar 31, 2025 | 8.32 |
| Mar 31, 2025 | 8.32 |
| Dec 31, 2024 | 23,200.00 Bn |
| Dec 31, 2024 | 23,200.00 Bn |
| Sep 30, 2024 | 6.80 |
| Sep 30, 2024 | 6.80 |
| Jun 30, 2024 | 16.37 Mn |
| Jun 30, 2024 | 16.37 Mn |
| Mar 31, 2024 | 8.39 Mn |
| Mar 31, 2024 | 8.39 Mn |
| Dec 31, 2023 | 25.21 Mn |
| Dec 31, 2023 | 25.21 Mn |